These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 28988716)

  • 1. Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression.
    Willoughby JLS; Chan A; Sehgal A; Butler JS; Nair JK; Racie T; Shulga-Morskaya S; Nguyen T; Qian K; Yucius K; Charisse K; van Berkel TJC; Manoharan M; Rajeev KG; Maier MA; Jadhav V; Zimmermann TS
    Mol Ther; 2018 Jan; 26(1):105-114. PubMed ID: 28988716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo.
    Rajeev KG; Nair JK; Jayaraman M; Charisse K; Taneja N; O'Shea J; Willoughby JL; Yucius K; Nguyen T; Shulga-Morskaya S; Milstein S; Liebow A; Querbes W; Borodovsky A; Fitzgerald K; Maier MA; Manoharan M
    Chembiochem; 2015 Apr; 16(6):903-8. PubMed ID: 25786782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate.
    Zimmermann TS; Karsten V; Chan A; Chiesa J; Boyce M; Bettencourt BR; Hutabarat R; Nochur S; Vaishnaw A; Gollob J
    Mol Ther; 2017 Jan; 25(1):71-78. PubMed ID: 28129130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Serum Proteins on the Uptake and RNAi Activity of GalNAc-Conjugated siRNAs.
    Agarwal S; Allard R; Darcy J; Chigas S; Gu Y; Nguyen T; Bond S; Chong S; Wu JT; Janas MM
    Nucleic Acid Ther; 2021 Aug; 31(4):309-315. PubMed ID: 33861634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of
    Ayyar VS; Song D; Zheng S; Carpenter T; Heald DL
    J Pharmacol Exp Ther; 2021 Nov; 379(2):134-146. PubMed ID: 34413198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes.
    Matsuda S; Keiser K; Nair JK; Charisse K; Manoharan RM; Kretschmer P; Peng CG; V Kel'in A; Kandasamy P; Willoughby JL; Liebow A; Querbes W; Yucius K; Nguyen T; Milstein S; Maier MA; Rajeev KG; Manoharan M
    ACS Chem Biol; 2015 May; 10(5):1181-7. PubMed ID: 25730476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolically Stable Anomeric Linkages Containing GalNAc-siRNA Conjugates: An Interplay among ASGPR, Glycosidase, and RISC Pathways.
    Kandasamy P; Mori S; Matsuda S; Erande N; Datta D; Willoughby JLS; Taneja N; O'Shea J; Bisbe A; Manoharan RM; Yucius K; Nguyen T; Indrakanti R; Gupta S; Gilbert JA; Racie T; Chan A; Liu J; Hutabarat R; Nair JK; Charisse K; Maier MA; Rajeev KG; Egli M; Manoharan M
    J Med Chem; 2023 Feb; 66(4):2506-2523. PubMed ID: 36757090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-Acetylgalactosamine Block-co-Polycations Form Stable Polyplexes with Plasmids and Promote Liver-Targeted Delivery.
    Dhande YK; Wagh BS; Hall BC; Sprouse D; Hackett PB; Reineke TM
    Biomacromolecules; 2016 Mar; 17(3):830-40. PubMed ID: 26854615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates.
    Brown CR; Gupta S; Qin J; Racie T; He G; Lentini S; Malone R; Yu M; Matsuda S; Shulga-Morskaya S; Nair AV; Theile CS; Schmidt K; Shahraz A; Goel V; Parmar RG; Zlatev I; Schlegel MK; Nair JK; Jayaraman M; Manoharan M; Brown D; Maier MA; Jadhav V
    Nucleic Acids Res; 2020 Dec; 48(21):11827-11844. PubMed ID: 32808038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates.
    Foster DJ; Brown CR; Shaikh S; Trapp C; Schlegel MK; Qian K; Sehgal A; Rajeev KG; Jadhav V; Manoharan M; Kuchimanchi S; Maier MA; Milstein S
    Mol Ther; 2018 Mar; 26(3):708-717. PubMed ID: 29456020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing.
    Nair JK; Willoughby JL; Chan A; Charisse K; Alam MR; Wang Q; Hoekstra M; Kandasamy P; Kel'in AV; Milstein S; Taneja N; O'Shea J; Shaikh S; Zhang L; van der Sluis RJ; Jung ME; Akinc A; Hutabarat R; Kuchimanchi S; Fitzgerald K; Zimmermann T; van Berkel TJ; Maier MA; Rajeev KG; Manoharan M
    J Am Chem Soc; 2014 Dec; 136(49):16958-61. PubMed ID: 25434769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.
    Springer AD; Dowdy SF
    Nucleic Acid Ther; 2018 Jun; 28(3):109-118. PubMed ID: 29792572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates.
    Nair JK; Attarwala H; Sehgal A; Wang Q; Aluri K; Zhang X; Gao M; Liu J; Indrakanti R; Schofield S; Kretschmer P; Brown CR; Gupta S; Willoughby JLS; Boshar JA; Jadhav V; Charisse K; Zimmermann T; Fitzgerald K; Manoharan M; Rajeev KG; Akinc A; Hutabarat R; Maier MA
    Nucleic Acids Res; 2017 Nov; 45(19):10969-10977. PubMed ID: 28981809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of
    McDougall R; Ramsden D; Agarwal S; Agarwal S; Aluri K; Arciprete M; Brown C; Castellanos-Rizaldos E; Charisse K; Chong S; Cichocki J; Fitzgerald K; Goel V; Gu Y; Guenther D; Habtemariam B; Jadhav V; Janas M; Jayaraman M; Kurz J; Li J; Liu J; Liu X; Liou S; Maclauchlin C; Maier M; Manoharan M; Nair JK; Robbie G; Schmidt K; Smith P; Theile C; Vaishnaw A; Waldron S; Xu Y; Zhang X; Zlatev I; Wu JT
    Drug Metab Dispos; 2022 Jun; 50(6):781-797. PubMed ID: 34154993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic Pharmacokinetics and Pharmacodynamics of GalNAc-siRNA: Translational Model Involving Competitive Receptor-Mediated Disposition and RISC-Dependent Gene Silencing Applied to Givosiran.
    Ayyar VS; Song D
    J Pharm Sci; 2024 Jan; 113(1):176-190. PubMed ID: 37871778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligand conjugate SAR and enhanced delivery in NHP.
    Holland RJ; Lam K; Ye X; Martin AD; Wood MC; Palmer L; Fraser D; McClintock K; Majeski S; Jarosz A; Lee ACH; Thi EP; Judge A; Heyes J
    Mol Ther; 2021 Oct; 29(10):2910-2919. PubMed ID: 34091052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GalNAc bio-functionalization of nanoparticles assembled by electrostatic interactions improves siRNA targeting to the liver.
    Korin E; Bejerano T; Cohen S
    J Control Release; 2017 Nov; 266():310-320. PubMed ID: 28987883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications.
    D'Souza AA; Devarajan PV
    J Control Release; 2015 Apr; 203():126-39. PubMed ID: 25701309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc
    Wang Y; Yu RZ; Henry S; Geary RS
    Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):475-485. PubMed ID: 31144994
    [No Abstract]   [Full Text] [Related]  

  • 20. ASGPR-Mediated Uptake of Multivalent Glycoconjugates for Drug Delivery in Hepatocytes.
    Monestier M; Charbonnier P; Gateau C; Cuillel M; Robert F; Lebrun C; Mintz E; Renaudet O; Delangle P
    Chembiochem; 2016 Apr; 17(7):590-4. PubMed ID: 26781030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.